SEC Form 4 · accession 0001209191-15-010576
Paratek Pharmaceuticals, Inc. · PRTK
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Thomas John Dietz
Director
Period of report
Feb 4, 2015
Accepted (ET)
Feb 6, 2015 · 9:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001178711
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1,F2 | $24.07 | Feb 4, 2015 | A | 20,000 | A | — | Feb 3, 2025 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1The exercise price is equal to the closing sales price per share of Common Stock as reported on The Nasdaq Global Market on the date of grant.
- F21/36th of the shares vest on a monthly basis.